TScan Therapeutics, Inc.
TCRX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.17 | 0.10 | -0.13 | 0.46 |
| FCF Yield | -18.36% | -21.86% | -7.71% | -4.95% |
| EV / EBITDA | -2.34 | -3.72 | -8.33 | -19.65 |
| Quality | ||||
| ROIC | -14.13% | -11.77% | -10.81% | -9.97% |
| Gross Margin | 100.00% | 100.00% | -6.92% | 100.00% |
| Cash Conversion Ratio | 0.91 | 0.90 | 1.10 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -20.77% | -24.86% | -36.56% | -40.75% |
| Free Cash Flow Growth | 11.69% | -38.23% | 3.37% | -8.13% |
| Safety | ||||
| Net Debt / EBITDA | 2.95 | 1.74 | 2.37 | 1.53 |
| Interest Coverage | -56.10 | -53.39 | -46.83 | -34.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -541.52 | -319.60 |